Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03439033 · ClinicalTrials.gov registry record · Phase 2
Comparison Study of PET/CT or PET/MRI Imaging to Magnetic Resonance Imaging (MRI) Alone in Men With Prostate Cancer
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 273
- Enrollment target
NCT03439033 is a Phase 2 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 273 participants.
The verdict
NCT03439033, a Phase 2 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 273 participants
- Enrollment target
Study Summary
This is a study primarily comparing Magnetic Resonance Imaging (MRI) alone to Positron Emission Tomography (PET)/MRI using an experimental tracer, 68Ga-PSMA-HBED-CC, among men with prostate cancer or prostatic cancer recurrence/metastasis. It is hypothesized that this comparison will demonstrate that PET using the tracer, 68Ga-PSMA-HBED-CC, is more sensitive than MRI alone. Potential subjects who cannot undergo MRI may undergo PET/CT instead.
Interventions
- DRUG PET/MRI with Gallium-68 labeled PSMA-HBED-CC
- DRUG Multiple PET/MRI with Gallium-68 labeled PSMA-HBED-CC
- DRUG PET/CT with Gallium-68 labeled PSMA-HBED-CC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 273 participants |
| Start Date | 2018-04-03 |
| Est. Completion | 2021-05-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03439033
The ClinicalTrials.gov registry entry for NCT03439033 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 273 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PET/MRI with Gallium-68 labeled PSMA-HBED-CC is the first listed.
NCT03439033 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03439033 about?
NCT03439033 is a clinical study titled "Comparison Study of PET/CT or PET/MRI Imaging to Magnetic Resonance Imaging (MRI) Alone in Men With Prostate Cancer". This is a study primarily comparing Magnetic Resonance Imaging (MRI) alone to Positron Emission Tomography (PET)/MRI using an experimental tracer, 68Ga-PSMA-HBED-CC, among men with prostate cancer or prostatic cancer recurrence/metastasis. It is hypothesized that this comparison will demonstrate tha...
What is the current status of trial NCT03439033?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 273 participants. The study started on 2018-04-03. Estimated completion is 2021-05-05.
What interventions are being tested in trial NCT03439033?
The interventions under investigation include: PET/MRI with Gallium-68 labeled PSMA-HBED-CC (DRUG), Multiple PET/MRI with Gallium-68 labeled PSMA-HBED-CC (DRUG), PET/CT with Gallium-68 labeled PSMA-HBED-CC (DRUG).
Who is sponsoring clinical trial NCT03439033?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.